Incidence of cerebrovascular and cardiovascular diseases, such as cerebral infarction and myocardial infarction caused by hypertension, can lead directly to death, or leave patients bedridden or with speech disabilities, which can result in a considerable decrease in the quality of life (QOL) of the patients, as well as their families. Meanwhile, OMRON Healthcare will forge a business partnership with its new American partner in which the two companies will have mutual access to the premium products and services that they offer in the cardiovascular disease (CVD) field, thereby increasing its ongoing efforts to "zero cerebral and cardiovascular events." With this agreement, OMRON Corporation will contribute capital in the amount of USD25 million (approx. (Headquarters: Mountain View, California, U.S., CEO: Vic Gundotra, hereinafter referred to as "AliveCor"), which provides diagnosis and treatment support services for atrial fibrillation (AF) *1 in the U.S. (Head Office: Muko, Kyoto, Japan, President & CEO: Isao Ogino, hereinafter referred to as "OMRON Healthcare") announced today an agreement to form capital and business partnerships with AliveCor, Inc.
0 Comments
Leave a Reply. |